Accuray develops, manufactures, and sells radiation therapy systems used by hospitals, cancer centers, and standalone treatment facilities to deliver targeted radiation for cancerous and benign tumors and selected neurological disorders. The company operates two primary hardware platforms: CyberKnife and a helical ring-gantry portfolio built on TomoTherapy technology. CyberKnife uses a robotic linear accelerator and real-time motion tracking to deliver stereotactic radiosurgery and stereotactic body radiation therapy while adjusting for patient and tumor movement. The helical portfolio includes the Stellar, Radixact, and Helix systems, as well as the Tomo C system produced through a joint venture in China. Both platforms are supported by integrated treatment planning and data management software. Accuray generates revenue through upfront capital equipment sales and recurring multi-year service contracts covering system maintenance, parts, software upgrades, and remote diagnostics. The company sells systems directly in the U.S., Western Europe, Japan, and other mature markets, and relies on distributor networks across emerging markets.